Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Data ReadoutpositiveGiredestrantPositive
AI Analysis
Summary
Genentech announced Phase 3 evERA trial data showing that giredestrant in combination therapy significantly improved progression-free survival in patients with ER-positive advanced breast cancer, with results published in The New England Journal of Medicine.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer
Importance:8/10
Sentiment:
0.80
breast cancerER-positivePhase 3progression-free survivalclinical dataNEJM publication
Related Companies
Read the original article
Published by yahoo_finance on October 1, 2026 5:00 AM